Compare VRA & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRA | RFL |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Real Estate |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 54.4M |
| IPO Year | 2010 | N/A |
| Metric | VRA | RFL |
|---|---|---|
| Price | $2.28 | $1.24 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 96.8K |
| Earning Date | 12-11-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $332,526,000.00 | $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $1.71 | $1.17 |
| 52 Week High | $5.79 | $3.19 |
| Indicator | VRA | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.32 | 45.41 |
| Support Level | $2.52 | $1.20 |
| Resistance Level | $2.99 | $1.29 |
| Average True Range (ATR) | 0.31 | 0.06 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 3.43 | 58.33 |
Vera Bradley Inc designs women's handbags, travel items, and accessories. Each category comprises a substantial component of total sales, with the bags category comprising the majority of the company's sales are made directly to customers through Vera Bradley's retail stores and e-commerce sites. The company also has a substantial wholesale business selling to specialty retail and department stores. Almost all company sales are in the United States. Vera Bradley uses third-party manufacturers in Asia to produce its products, and the company distributes the products through its distribution center in Indiana. The Company has three reportable segments: Vera Bradley Direct, Vera Bradley Indirect, and Pura Vida. The majority of revenue is from the Vera Bradley Direct segment.
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.